CNIO–Lilly Cell Signalling and Immunometabolism Section

Home | Research & Innovation | Scientific Programmes | Experimental Therapeutics Programme | CNIO–Lilly Cell Signalling and Immunometabolism Section

Research Scientists

  • Roberto Gómez
  • Sonia Hernández
  • Eva Pilar Lospitao
  • Carolina Maestre
  • Gloria Martínez del Hoyo

Technicians

  • Jenniffer Patricia Condo
  • Laura Diezma
  • Alicia Luengo
  • Sandra Peregrina
  • María Jesús Valle

Our laboratory, in collaboration with Lilly, works on the identification and validation of cellular models of Chromosomal instability (CIN) and novel dependencies as a result of CIN. We apply bespoke functional genomic screens to uncover novel vulnerabilities, in combination with in vitro and in vivo approaches, to obtain a complete understanding of the role of CIN in tumour development and anti-tumour response. Each potential target goes through a validation process using xenografts, allografts, and mouse models developed at the CNIO. Our work includes the use of non-invasive in vivo imaging technologies, and histochemical characterisation of tumours, using a variety of intrinsic and extrinsic tumour markers. The final step is the validation in human samples using tumour tissue arrays.

Recent publications

Up

CNIO
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.